Sinovac Set to Move Listing to NASDAQ

Sinovac Biotech Ltd. (SVA) will move the home for its stock listing from the NYSE Amex to the NASDAQ Global Market. The reason given for the change was “greater liquidity.” Target day for the transfer is November 16. Although most NASDAQ companies use a four-letter symbol, Sinovac will be allowed to keep its current three-letter identifier, SVA, so the new listing will not have a great effect on most investors.

Sinovac makes vaccines, most of which are sold in China. Its Healive vaccine for hepatitis B is the company’s mainstay product, though it has generated a great deal of news during the last six months with its H1N1 swine flu vaccine and the spillover of interest into its seasonal flu vaccine as well.

Disclosure: none.

Comments

[fran grady:]

Does this move increase the number of potential investors?

Nov 04 09:24 AM

[User 283977:]

Hi Fran...

this is what Mr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, "… we believe a NASDAQ listing will provide Sinovac with opportunities to increase investor and analyst interest and provide our investors with a better environment for trading our shares."

Nov 04 09:40 AM

[User 368368:]

The specialist was keeping SVA down to be able to buy back all the stock he had to sell short when buying drove the stock to 12.50. SVA only has 43 million stock outstanding and several million shares are held by institutions alone. So how did they trade 49 million shares in one day? It is a lot of shares the specialist has to buy back to break even or make a profit for his company. I think SVA management was disappointed in the stock price movement under the specialist system and decided to go to NASDAQ. This move will be great for good news, but it is a double edged sword and could cut deep on bad news.

Nov 07 10:35 PM

[User 507387:]

That SVA moves to NASDAQ means more price fluctuation in the future?
Another question. SVA will have a conference, see below news. I also see a statement says that "The next earnings announcement from SVA is expected the week of November 30, 2009." They are contradictary? Or not. Thanks.


......
Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Monday, November 16, 2009 at 9:00 a.m. ET to review the Company's third quarter financial results for the period ended September 30, 2009 and provide an update on recent corporate developments.

Nov 11 08:34 PM

[Talavera:]

The Talavera indicators chart show sva as a winner for
this comming new year I am buying 1000 shares on monday for sure.

Nov 13 11:06 AM

[User 282993:]

This stock has proven it's a winner in more ways than one. As soon as it can fullfill it's China contracts which will happen in thirty days, it should really start to move. It will be going all over the world. It already is touching Mexico. Smart management and that counts for a lot. Now that it is on an American exchange this is going to be a buy and hold stock until great growth levels out. I bought and sold, made money but lost out on more quick growth. I've gone in again and will hold.

Nov 16 08:20 AM